CellWell record HH-149096
Selenium supplementation in individuals with newly diagnosed Graves' hyperthyroidism: a double-blind, multi-centre RCT
Cramon PK; Winther KH; Boesen VB; Larsen CB; Bjorner JB; Nordqvist SF; Forman JL; Juul AB; Bach-Mortensen P; Knudsen N; Nolsøe RL; Vilsbøll T; Andries A; Gram J; Nygaard B; Demircan K; Chillon TS; Schomburg L; Hegedüs L; Bonnema SJ; Feldt-Rasmussen U; Rasmussen ÅK; Watt T
European thyroid journal · 2026
In plain language
In the GRASS trial, daily selenium supplementation did not improve remission rates or quality of life in newly diagnosed Graves' hyperthyroidism compared with placebo.
- Evidence
- Established
- Design
- Randomized controlled trial
Cite this record: https://thecellwell.org/studies/HH-149096
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.